37 completed, 21 unknown, 10 terminated, 5 recruiting. 30 Phase 2, 20 Phase 3, 16 Phase 4, 12 Not applicable, 5 Phase 1.
Follow Amantadine: new trials by email Literature Review of Amantadine trials Research Report on Amantadine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Amantadine (oral) - Breast Cancer, Peripheral Neuropathy Due to Chemotherapy | Phase 2 | Not yet recruiting | Al-Azhar University | 80 | 2026-12-01 | 2026-10-22 |
| Use of Gocovri to Improve Disability Due to Radiation Encephalopathy Gocovri (extended-release amantidine) - Encephalopathy, Radiation Effect | Phase 2 | Not yet recruiting | Weill Medical College of Cornell University | 24 | 2026-09-01 | 2026-08-03 |
| Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome Pregabalin, Pregabalin + Amantadine, Pregabalin + Duloxetine - Amantadine, Duloxetine | Not applicable | Recruiting | Cairo University | 150 | 2026-02-21 | 2026-02-24 |
| A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling - Long COVID, Post-Acute COVID-19 Syndrome | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2025-06-01 | 2025-08-26 | |
| The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial Amantadine (100mg) as add on therapy., Placebo - Parkinson Disease (PD) | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 132 | 2025-05-01 | 2025-02-10 |
| A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease propranolol, Amantadine - Parkinson Disease (PD), Tremor | Not applicable | Completed | Multan Medical And Dental College | 220 | 2024-07-05 | 2025-08-08 |
| Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI). Amantadine Hydrochloride, Placebo - Traumatic Brain Injury | Phase 2 | Active not recruiting | SHINKEI Therapeutics, Inc | 45 | 2024-06-01 | 2025-07-15 |
| Amantadine Therapy for Cognitive Impairment in Long COVID Amantadine - Long COVID, Post-COVID19 Condition | Phase 2 | Completed | Ohio State University | 64 | 2023-12-07 | 2026-01-27 |
| Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU Cerebrolysin, amantadine sulfate - Traumatic Brain Injury | Phase 3 | Completed | Ain Shams University | 150 | 2023-09-01 | 2025-11-19 |
| Amantadine for Neuroenhancement in Acute Patients Study Amantadine - Disorder of Consciousness | Phase 2 | Unknown | University Hospital Tuebingen | 50 | 2023-03-01 | 2024-02-01 |
| The Effect of Amantadine on Post-COVD-19 Fatigue Amantadine - Post-COVID-19 Syndrome | Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 83 | 2022-12-26 | 2022-12-28 |
| Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis Transcranial Magnetic Stimulation, Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule - Multiple Sclerosis, Fatigue | Phase 3 | Unknown | Hospital San Carlos, Madrid | 144 | 2022-11-28 | 2023-12-11 |
| Promoting Recovery After STroke With Amantadine Amantadine, Placebo - Stroke, Ischemic, Stroke Hemorrhagic | Phase 2 | Recruiting | University of Pennsylvania | 60 | 2022-02-01 | 2026-03-30 |
| Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression Quetiapine, Amantadine, Pramipexole - Treatment Resistant Depression | Phase 4 | Unknown | All India Institute of Medical Sciences, Bhubaneswar | 150 | 2021-08-07 | 2023-08-22 |
| Amantadine for COVID-19 Amantadine, Lactose monohydrate - Covid19 | Phase 3 | Unknown | Copenhagen University Hospital, Hvidovre | 226 | 2021-06-01 | 2021-10-06 |
| Efficacy of Amantadine Treatment in COVID-19 Patients Amantadine - Patients With Moderate or Severe COVID-19 | Phase 3 | Terminated | Noblewell | 193 | 2021-03-30 | 2022-09-30 |
| The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms Amantadine Hydrochloride, Placebo - COVID-19, SARS-CoV-2 | Phase 3 | Unknown | Independent Public Clinical Hospital No. 4 in Lublin | 200 | 2021-03-15 | 2021-08-13 |
| Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease GOCOVRI - Parkinson Disease | Phase 4 | Completed | Oregon Health and Science University | 8 | 2020-11-05 | 2024-10-10 |
| Impact of Amantadine on Traumatic Brain Injury Amantadine (100mg) as add on therapy., Placebo - Trauma, Brain | Phase 4 | Completed | Damanhour University | 50 | 2020-09-30 | 2023-04-07 |
| Changes in Glutamatergic Neurotransmission of Severe TBI Patients Amantadine + L-DOPA, NMDA blocker - Disorder of Consciousness, Traumatic Brain Injury | Early Phase 1 | Suspended | Weill Medical College of Cornell University | 30 | 2020-09-23 | 2022-09-30 |
Showing 20 of 82. Sign in to see all of them.
Parkinson Disease (15) · Brain Injuries, Traumatic (12) · Dyskinesias (8) · COVID-19 (5) · Cocaine-Related Disorders (5) · Hepatitis C, Chronic (5) · Brain Injuries (4) · Consciousness Disorders (4) · Influenza, Human (4) · Parkinsonian Disorders (4) · Schizophrenia (4) · Coma (3) · Post-Acute COVID-19 Syndrome (3) · Psychotic Disorders (3) · Substance-Related Disorders (3)
Adamas Pharmaceuticals, Inc. (3) · University Hospital, Toulouse (3) · Wake Forest University Health Sciences (3) · Ain Shams University (2) · Consorci Sanitari de Terrassa (2) · Johns Hopkins University (2) · National Institute on Drug Abuse (NIDA) (2) · Oregon Health and Science University (2) · Rabin Medical Center (2) · Rush University Medical Center (2) · University of Manitoba (2) · University of Pennsylvania (2) · Weill Medical College of Cornell University (2) · Aga Khan University (1) · Al-Azhar University (1)
United States (36) · France (9) · Canada (8) · Egypt (6) · Germany (6) · Spain (5) · Israel (4) · Australia (2) · Brazil (2) · China (2) · Denmark (2) · Iran (2) · Mexico (2) · Netherlands (2) · Pakistan (2)
Angela Dentiste, MBA (2) · Christopher G Goetz, MD (2) · John Rotrosen, M.D. (2) · Olivier Rascol, MD (2) · Abualauon Elpiplaoy, MD (1) · Adam Barczyk, Prof. (1) · Aeyal Raz, MD,PhD (1) · Alin O Stirban, MD (1) · Amie Hiller, MD (1) · Amy Mathews, M.D. (1) · Andreea Nissenkorn, MD (1) · Andrew I Schamess, MD (1)
PMID 39459868, PMID 10030449, PMID 10082232, PMID 1026855, PMID 10580511, PMID 10646846, PMID 11302933, PMID 11478689, PMID 11814066, PMID 11814067, PMID 12648190, PMID 14211150, PMID 15374380, PMID 1581359, PMID 1629283, PMID 16697124, PMID 18058285, PMID 18074029, PMID 19752841, PMID 1998945, PMID 20729740, PMID 20840778, PMID 21672497, PMID 22375973, PMID 22550086, PMID 22755276, PMID 23264438, PMID 24045608, PMID 2493102, PMID 25251457, PMID 25774566, PMID 27733282, PMID 27848269, PMID 28891908, PMID 28958678, PMID 29113955, PMID 29742960, PMID 3280212, PMID 3322538, PMID 33242419, PMID 35390511, PMID 35798516, PMID 36647114, PMID 36725099, PMID 36931576, PMID 37608315, PMID 38145314, PMID 38176857, PMID 39060125, PMID 39307154
2023 (1), P50DA009250 (1), P50DA009260 (1), P50DA012756 (1)